Today: 19 May 2026
Browse Category

NASDAQ:SRPT 2 October 2025 - 26 January 2026

Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data

Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data

Sarepta Therapeutics shares rose 6.5% to $22.51 in early premarket trading Monday, following a 9.65% after-hours surge Friday ahead of new Elevidys trial data. Investors await three-year results from the Phase 3 EMBARK study in Duchenne muscular dystrophy, with safety concerns heightened after FDA restrictions and patient deaths. About 17,600 shares changed hands premarket, according to Public.com.
26 January 2026
·
Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

Sarepta shares rose about 5% in after-hours trading Friday after the company announced it will release three-year Phase 3 data for its Duchenne gene therapy, Elevidys, on Jan. 26. The update follows recent FDA restrictions and safety warnings after deaths in non-ambulatory patients. Investors are watching for data on durability and safety. Sarepta will hold a webcast Monday morning to present the results.
24 January 2026
··
Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta Therapeutics shares fell 13% to $20.73 Monday after a preliminary update showed weaker-than-expected fourth-quarter sales for its Duchenne gene therapy, Elevidys. The company reported $110.4 million in Elevidys revenue for the quarter, below Wall Street’s $122 million estimate. Sarepta cited a severe flu season and delayed six patient infusions to 2026. Final results are due in late February.
12 January 2026
·
Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025

Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025

Sarepta Therapeutics shares traded near $22 on Dec. 16, 2025, valuing the company at roughly $2–$3 billion. The company expects to close a $291.4 million convertible debt exchange on Dec. 18, shifting debt maturities and adding $31.6 million in cash. ELEVIDYS remains under scrutiny after the FDA added a boxed warning for serious liver risks in November.
16 December 2025
·
SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Sarepta shares closed Monday at $18.90, up 6.9%, after a positive safety update for its experimental RNA therapy SRP‑1003. The company hit an enrollment milestone in its DM1 trial, triggering a $200 million payment to Arrowhead Pharmaceuticals. SRPT stock remains down about 85% year-to-date following setbacks with its gene therapy Elevidys.
25 November 2025
····
European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

Wall Street on Edge: Bank Chiefs Warn 10–15% Pullback as Fed Flies Blind—Futures Slide, Big Tech Wobbles (Nov. 4, 2025)

S&P 500, Nasdaq-100, and Dow futures fell pre-market as bank CEOs warned of stretched tech valuations and possible drawdowns. The VIX hovered near a two-week high. Official U.S. economic data remained limited due to the government shutdown, with traders awaiting ADP’s jobs report. Palantir and Sarepta shares dropped, while Spotify rose; Uber fell on cautious guidance.
4 November 2025
················
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta (SRPT) Stock Collapses 80% on FDA Bombshell – Is a Big Rebound Coming?

Sarepta Therapeutics shares plunged nearly 80% in 2025, falling from a high of $138.81 to around $15 after its Phase 3 ESSENCE trial failed and the FDA halted gene therapy trials following patient deaths. Q3 revenue beat estimates at $399.4 million, but the company posted a $179.9 million net loss. Sarepta restricted Elevidys sales to ambulatory patients after the FDA intervention. Analyst consensus is Hold, with a $34.50 average price target.
4 November 2025
··
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks

Palantir shares rose after Q3 results beat estimates and the company raised its outlook for a third straight quarter, citing surging AI platform demand. Hims & Hers stock jumped 7% post-market as it entered talks to offer Novo Nordisk’s Wegovy, despite mixed earnings. Sarepta plunged over 20% after a key Duchenne drug trial failed its main goal. Sanmina soared 18% on a strong earnings beat and guidance far above Wall Street forecasts.
4 November 2025
·······
Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained

Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained

The FDA on July 28, 2025, cleared Elevidys gene therapy shipments for ambulatory patients after finding no link to a child’s death, while Sarepta added black-box liver warnings. Sarepta’s Q2 revenue jumped 68% to $611.1 million, but shares plunged 85% YTD before rebounding to $22.35 after the FDA decision. The EU’s CHMP issued a negative opinion on Elevidys, delaying European approval. Sarepta cut 36% of its workforce in July.
3 October 2025
··
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

SRPT closed at $19.57 on Oct 2, up 6.8% for the day and nearly 16% over the past month, but remains down about 82% year-to-date. The company restructured in July, cutting 500 jobs and pausing some gene therapy trials after FDA safety concerns. Sarepta resumed shipments of Elevidys for ambulatory DMD patients following FDA guidance. Analyst consensus is “Hold,” with price targets ranging from $14 to $39.
2 October 2025
··

Stock Market Today

  • JBS Q1 2026 Earnings Review and Valuation Amid Brazil-USA Summit
    May 19, 2026, 1:38 AM EDT. JBS reported Q1 2026 sales of $21.6 billion and net income of $220.6 million, yet its share price dropped 27.4% over 30 days, reflecting weak short-term momentum. Trading at $12.86, JBS is viewed as 35.8% undervalued versus a fair value of $20.04, driven by expectations of global protein demand growth and multi-protein platform advantages. Risks include tight U.S. cattle supply and rising input costs impacting margins and cash flow. Investors should weigh long-term growth potential against these pressures, considering JBS's mixed earnings and current market pricing in their investment decisions.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Dominion Energy Shares Move After NextEra’s $67 Billion Plan Seen as AI Power Play

Dominion Energy Shares Move After NextEra’s $67 Billion Plan Seen as AI Power Play

19 May 2026
NextEra Energy agreed to acquire Dominion Energy in a $66.8 billion all-stock deal, sending Dominion shares up 9.4% to $67.56 while NextEra fell 4.6%. Dominion holders would get 0.8138 NextEra share per Dominion share and a $360 million cash payment. The deal requires multiple regulatory approvals. Dominion’s Coastal Virginia Offshore Wind project remains a focus after cutting costs to $11.4 billion.
Go toTop